EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Inhaled RNA drugs to treat lung diseases: Disease-related cells and nano–bio interactions

Mengjun Zhang, Haoyu Lu, Liangkun Xie, Xulu Liu, Dongmei Cun, Mingshi Yang

Advanced Drug Delivery Reviews · 2023-12 · 203 · 115144

DOI: 10.1016/j.addr.2023.115144 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2023-12. Verfasst von Mengjun Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Wuya College of Innovation, Shenyang Pharmaceutical University, Wenhua Road No. 103, 110016 Shenyang, China; School of Pharmacy, Henan University, Ka…. Hauptthemen laut MEDLINE: Lung Diseases, Pulmonary Disease, Chronic Obstructive, Cystic Fibrosis, Asthma. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 182 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In recent years, RNA-based therapies have gained much attention as biomedicines due to their remarkable therapeutic effects with high specificity and potency. Lung diseases offer a variety of currently undruggable but attractive targets that could potentially be treated with RNA drugs. Inhaled RNA drugs for the treatment of lung diseases, including asthma, chronic obstructive pulmonary disease, cystic fibrosis, and acute respiratory distress syndrome, have attracted more and more attention. A variety of novel nanoformulations have been designed and attempted for the delivery of RNA drugs to the lung via inhalation. However, the delivery of RNA drugs via inhalation poses several challenges. It includes protection of the stability of RNA molecules, overcoming biological barriers such as mucus and cell membrane to the delivery of RNA molecules to the targeted cytoplasm, escaping endosomal entrapment, and circumventing unwanted immune response etc. To address these challenges, ongoing researches focus on developing innovative nanoparticles to enhance the stability of RNA molecules, improve cellular targeting, enhance cellular uptake and endosomal escape to achieve precise delivery of RNA drugs to the intended lung cells while avoiding unwanted nano-bio interactions and off-target effects. The present review first addresses the pathologic hallmarks of different lung diseases, disease-related cell types in the lung, and promising therapeutic targets in these lung cells. Subsequently we highlight the importance of the nano-bio interactions in the lung that need to be addressed to realize disease-related cell-specific delivery of inhaled RNA drugs. This is followed by a review on the physical and chemical characteristics of inhaled nanoformulations that influence the nano-bio interactions with a focus on surface functionalization. Finally, the challenges in the development of inhaled nanomedicines and some key aspects that need to be considered in the development of future inhaled RNA drugs are discussed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung DiseasesPulmonary Disease, Chronic ObstructiveCystic FibrosisAsthmaHumansRNALungPharmaceutical PreparationsAdministration, InhalationDrug Delivery Systems

Stichwörter der Autor:innen

InhalationLung diseasesNano–bio interactionsRNA drugs

Substanzen

RNAPharmaceutical Preparations

Autor:innen und Institutionen

  • Wuya College of Innovation, Shenyang Pharmaceutical University, Wenhua Road No. 103, 110016 Shenyang, China; School of Pharmacy, Henan University, Kaifeng 475004, China.
  • Wuya College of Innovation, Shenyang Pharmaceutical University, Wenhua Road No. 103, 110016 Shenyang, China.
  • Wuya College of Innovation, Shenyang Pharmaceutical University, Wenhua Road No. 103, 110016 Shenyang, China. Electronic address: cundongmei@163.com.
  • Wuya College of Innovation, Shenyang Pharmaceutical University, Wenhua Road No. 103, 110016 Shenyang, China; Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2…

Zitieren

APA

Zhang, M., Lu, H., Xie, L., Liu, X., Cun, D., & Yang, M. (2023). Inhaled RNA drugs to treat lung diseases: Disease-related cells and nano–bio interactions. Advanced Drug Delivery Reviews, 203, 115144. https://doi.org/10.1016/j.addr.2023.115144

Vancouver

Zhang M, Lu H, Xie L, Liu X, Cun D, Yang M. Inhaled RNA drugs to treat lung diseases: Disease-related cells and nano–bio interactions. Advanced Drug Delivery Reviews. 2023;203:115144. doi:10.1016/j.addr.2023.115144

BibTeX
@article{Zhang2023,
  author = {Zhang, Mengjun and Lu, Haoyu and Xie, Liangkun and Liu, Xulu and Cun, Dongmei and Yang, Mingshi},
  title = {Inhaled RNA drugs to treat lung diseases: Disease-related cells and nano–bio interactions},
  journal = {Advanced Drug Delivery Reviews},
  year = {2023},
  volume = {203},
  pages = {115144},
  doi = {10.1016/j.addr.2023.115144}
}
Kostenlos starten →